Verici Dx Publishes Study on Gene Signature Test for Kidney Transplant Rejection Prediction
Verici Dx has published a peer-reviewed validation study for its Pre-Transplant Rejection Assessment (PTRA) test, which predicts the risk of acute rejection in kidney transplant recipients within the first two months post-transplant. This advanced clinical diagnostic tool aims to enhance patient stratification for deceased donor kidney transplants.
FRANKLIN, Tenn.–(BUSINESS WIRE)–Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assa